AI-generated from publicly available materials.Aeon has successfully raised its seed funding to over €12 million while also acquiring Aware Health, a German blood diagnostics platform.
The Zurich-based startup, which previously secured €8.2 million in June 2025, integrates advanced technologies such as whole-body MRI, blood diagnostics, and genetic risk analysis, all enhanced by AI. This innovative approach aims to identify health trends and predict individual health risks. Aeon's MRI capabilities can detect over 500 anomalies across various body systems, while its blood tests analyze more than 100 biomarkers, providing crucial health information.
The acquisition of Aware Health adds significant value to Aeon by incorporating its technology, contracts, customer relationships, and essential personnel. Tim Seithe, Aeon's founder and CEO, emphasized the company's commitment to transforming preventive healthcare from a reactive to a proactive model. He noted that the integration of imaging and blood diagnostics, powered by AI, facilitates predictive insights into health trajectories.
This funding round, co-led by Araya Ventures alongside other investors, underscores the growing recognition of Aeon's unique offerings in the European healthcare landscape. With a reported significant finding rate of 15.4% from check-ups, Aeon is positioned to redefine how health monitoring is approached, potentially setting new standards in preventive care.